Business context and reporting period
The supplied filing is Ekso Bionics Holdings, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2014; it does not identify Chronoscale Holdings Corp. as the registrant. Ekso develops and sells wearable robotic exoskeletons for medical and other markets and provides engineering services. The January 2014 merger made Ekso Bionics the accounting acquirer, so the comparative results principally reflect Ekso Bionics’ historical operations.
Financial performance and position
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $1.59 million | $0.83 million | $3.85 million | $2.51 million |
| Gross profit (margin) | $0.48 million (30%) | $0.30 million (36%) | $1.00 million (26%) | $0.72 million (29%) |
| Operating expenses | $4.21 million | $1.97 million | $12.94 million | $8.26 million |
| Operating loss | $3.73 million | $1.67 million | $11.93 million | $7.54 million |
| Net income (loss) | $12.02 million | ($1.89 million) | ($13.61 million) | ($9.09 million) |
| Operating cash flow | Management reports $3.6 million used | Not stated here | $12.30 million used | $6.76 million used |
Q3 net income was driven by a $15.77 million noncash gain from remeasuring warrant liabilities, not operating profitability. The company reported diluted Q3 loss per share of $0.04 after adjusting for that gain; basic income per share was $0.15. Nine-month basic and diluted loss per share were each $0.18.
Medical-device and engineering-services revenue increased year over year in Q3 by approximately 89% and 92%, respectively. For the nine months, they rose approximately 76% and 34%. Higher operating costs outpaced revenue growth, and gross margin declined in both comparisons.
At September 30, cash was $7.18 million, working capital was $5.8 million, total assets were $15.42 million, and total liabilities were $21.34 million. Stockholders’ deficit was $5.92 million, including accumulated deficit of $51.65 million. Notes payable totaled approximately $129,000; convertible debt had been settled or converted. Warrant liability was $11.82 million. Nine-month investing cash use was $0.81 million; financing provided $19.48 million, mainly from common-stock issuance.
Material changes, outlook, risks and unusual items
- The January 2014 merger and private placement materially changed the capital structure. The placement raised $25.3 million in cash, in addition to converting bridge notes; reported financing cash flow also reflects debt repayments.
- Management said September 30 cash was expected to fund the current business plan and obligations into the second quarter of 2015. It cautioned that additional financing may be needed; without it, the company may reduce spending or curtail operations. No revenue or earnings guidance was provided.
- On October 23, 2014, the company began a tender offer to amend and exercise up to 30.3 million placement warrants: exercise price would fall from $2.00 to $1.00, with a shortened exercise period and other restrictions. The company sought proceeds for operations and to reduce warrant liability. The filing does not state the offer’s outcome.
- FDA regulatory risk increased: following creation of a Class II category for powered exoskeletons, the FDA advised on October 24 that Ekso was not exempt from premarket notification and requested a meeting. A planned 510(k) filing could be deferred pending discussions; the filing warns the FDA could require the company to stop marketing Ekso GT during the clearance process.
- Management reported disclosure controls were not yet effective at September 30 and identified an unremediated material weakness involving, among other matters, cash and IT controls and the prior lack of an independent audit committee. Remediation was ongoing.
- Other risks include recurring operating losses and negative operating cash flow, fluctuating sales and delivery timing, dependence on financing, customer concentration, medical-device regulation and reimbursement, competition, and unhedged foreign-currency exposure. The company reported no material legal proceedings at quarter-end.
Important facts for investors to verify
- Confirm the intended issuer: this filing is for Ekso Bionics Holdings, Inc., not the company named in the request metadata.
- Review subsequent cash use, financing, and whether the stated runway into Q2 2015 was achieved.
- Check the tender-offer participation, proceeds raised, resulting warrant count and liability, and dilution to common shareholders.
- Track FDA discussions, 510(k) filing and clearance status, and any limits on Ekso GT marketing.
- Assess whether operating revenue growth can improve gross margins and cover the substantially higher operating expense base.
- Monitor remediation of the material weakness and effectiveness of disclosure and financial-reporting controls.